STAT+: Roche, Celcuity detail successful advanced breast cancer studies
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
BERLIN \u2014 They may be working on vastly different scales \u2014 the biotech Celcuity has a market cap of about $2 billion, while Roche reaped more than $60 billion in sales last year \u2014 but both companies unveiled data here Saturday that they hope will win them new approvals in breast cancer.\u00a0<\/p>\n
For Celcuity, the detailed results from a trial of its drug gedatolisib backed up the splash it made in July<\/a> when it disclosed its successful topline outcomes, an announcement that sent its share price soaring and earned descriptions like \u201cunprecedented\u201d from analysts. And for Roche, the data suggested its drug giredestrant may just work on a broader population than might have been expected, though it remains unclear how regulators will assess the medicine.\u00a0<\/p>\n Alessandra Gennari of Italy\u2019s University of Eastern Piedmont, who was the discussant for the two trials at a session during the European Society for Medical Oncology\u2019s annual conference, called them \u201ctwo potentially changing-practice trials.\u201d<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n